Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 5/20 | 0.78 |
| ▸ | HSPA5 | P11021 | 3/20 | 0.78 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | GAPDH | P04406 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | HBB | P68871 | 1/20 | 0.67 |
| ▸ | SLC28A2 | O43868 | 4/20 | 0.66 |
| ▸ | ADK | P55263 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 8-Chloroadenosine SCHEMBL19680324 | 1.00 | HSPA8 (0.78) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| 8-Chloroadenosine SCHEMBL26788558 | 1.00 | HSPA8 (0.78) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| 8-Chloroadenosine SCHEMBL987728 | 1.00 | HSPA8 (0.78) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| 8-Chloroadenosine SCHEMBL31064773 | 1.00 | HSPA8 (0.78) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| 8-Chloroadenosine SCHEMBL19668313 | 0.94 | HSPA8 (0.71) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| 8-Chloroadenosine SCHEMBL10531116 | 0.94 | HSPA8 (0.71) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| 8-Chloroadenosine SCHEMBL19668314 | 0.94 | HSPA8 (0.69) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| 8-Chloroadenosine SCHEMBL6275972 | 0.94 | HSPA8 (0.69) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| 8-Chloroadenosine SCHEMBL9752393 | 0.91 | HSPA8 (0.66) | HSPA8HSPA5RXFP1GAPDHHSD17B10 | |
| SCHEMBL12946772 | 0.91 | HSPA8 (0.64) | HSPA8HSPA5RXFP1GAPDHHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720329-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SensID GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20250268993-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | THERIVA BIOLOGICS, INC. | 2025-08-28 | — | — | US | claimed |
| US-12318434-B2 | Alkaline phosphate-based oncology treatments | THERIVA BIOLOGICS, INC. (US) | 2025-06-03 | — | — | US | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2024246014-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SENSID GMBH (DE) | 2024-12-05 | — | — | WO | claimed |
| EP-4467659-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS WITH A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSIS | SensID GmbH (DE) | 2024-11-27 | — | — | EP | claimed |
| CN-118217301-A | Pharmaceutical composition containing 8-chloroadenosine and homoharringtonine for synergistic treatment of AML | 宁波大学附属人民医院 | 2024-06-21 | — | — | CN | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| US-20220202914-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | THERIVA BIOLOGICS, INC. | 2022-06-30 | — | — | US | claimed |
| EP-3965805-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | Synthetic Biologics, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2019062919-A1 | METHOD FOR TREATING LEUKEMIA | OBI PHARMA, INC. (CN) | 2019-04-04 | — | — | WO | claimed |
| WO-2018127786-A1 | COMPOSITIONS AND METHODS FOR DETERMINING A TREATMENT COURSE OF ACTION | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2018-07-12 | — | — | WO | claimed |
| WO-2017207993-A1 | CANCER TREATMENTS | NUCANA BIOMED LIMITED (GB) | 2017-12-07 | — | — | WO | claimed |
| US-20130183289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC (US) | 2013-07-18 | — | — | US | claimed |
| EP-2200611-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen Idec MA, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009038684-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC. (US) | 2009-03-26 | — | — | WO | claimed |
| WO-2005120521-A2 | METHODS OF TREATING CANCER WITH 8-CHLORO-ADENOSINE | SOPHERION THERAPEUTICS (US) | 2005-12-22 | — | — | WO | claimed |
| US-6512004-B2 | Activation of kinase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-01-28 | — | — | US | claimed |
| US-20020142990-A1 | Promoters of neural regeneration | NIH-DEITR | 2002-10-03 | — | — | US | claimed |
| US-20020006916-A1 | Activation of kinase | NIH-DEITR | 2002-01-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | HSPA8 2551/4885HSPA5 1509/4885RXFP1 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.